Skip to Content

BioRestorative Therapies Inc BRTX

Morningstar Rating
$2.06 −0.04 (1.67%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

BRTX is trading at a 876% premium.
Price
$2.09
Fair Value
$9.43
Uncertainty
Extreme
1-Star Price
$79.64
5-Star Price
$7.49
Economic Moat
Scjj
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BRTX is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$2.09
Day Range
$2.032.19
52-Week Range
$1.037.13
Bid/Ask
$2.04 / $2.07
Market Cap
$13.91 Mil
Volume/Avg
336,255 / 2.1 Mil

Key Statistics

Price/Earnings (Normalized)
Price/Sales
69.30
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
11

Valuation

Metric
BRTX
Price/Earnings (Normalized)
Price/Book Value
0.98
Price/Sales
69.30
Price/Cash Flow
Price/Earnings
BRTX

Financial Strength

Metric
BRTX
Quick Ratio
4.77
Current Ratio
4.86
Interest Coverage
Quick Ratio
BRTX

Profitability

Metric
BRTX
Return on Assets (Normalized)
−3.65%
Return on Equity (Normalized)
−4.15%
Return on Invested Capital (Normalized)
−9.50%
Return on Assets
BRTX
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
XcpgtrbkTzrdb$637.8 Bil
Vertex Pharmaceuticals Inc
VRTX
HzzmgzlfWvjql$121.6 Bil
Regeneron Pharmaceuticals Inc
REGN
CfwrcwztfNnpgp$115.1 Bil
Moderna Inc
MRNA
BtdlnzrwZlft$51.5 Bil
argenx SE ADR
ARGX
VjjjyzmdYtclv$22.9 Bil
BioNTech SE ADR
BNTX
KdytmwtrQtmj$20.7 Bil
Alnylam Pharmaceuticals Inc
ALNY
VgwsbsglXqztvm$19.9 Bil
Biomarin Pharmaceutical Inc
BMRN
QsdksmrxsKtrkx$16.1 Bil
United Therapeutics Corp
UTHR
KqtqvcmzBxst$13.7 Bil
Incyte Corp
INCY
VzvgccgzVvwxc$12.3 Bil

Sponsor Center